Loading
Outlook Therapeutics, Inc. Stock: price and insider trades · United States
4 insiders bought €2.3M of shares over the last 90 days, the latest by Sukhtian Ghiath M., filed 14 Aug 2026.
Outlook Therapeutics, Inc.: what insiders have been doing
Outlook Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 23 October 2025 and 23 October 2026, 4 insiders published 4 filings.
Only purchases show up on the open market, 4 purchases in all worth €2.3M, filed by 4 insiders. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €2.2M, bought by Sukhtian Ghiath M. and made public on 14 August 2026 (1.5% of market cap). Among those who bought: 2 senior executives, 1 finance chief and 1 chief executive.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 4 filings, this issuer sits below that mark. Over the whole record (from 2016), the tally stands at 70 purchases and 25 sales. The 10-K for the year ended 30 September 2025 shows 1.4 m USD of revenue and -62.4 m USD of net income.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 14 August 2026, 71 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
144
Thresholds
n/a
Buy Volume
€31M
70 ops. · all time
Sell Volume
€2M
25 ops. · all time
Who traded when
BuySaleFaisal Ghiath Sukhtian1 buy
Ghiath M. Sukhtian1 buy
Lawrence A. Kenyon1 buy
Robert Charles Jahr1 buy
Since the insiders bought
- -22.6%Entry US$0.67 · Close 20 Oct 2026 US$0.52
- -50.0%Entry US$1.04 · Close 20 Oct 2026 US$0.52
- -80.1%Entry US$5.22 · Close at T+365 US$1.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$0.56
Analyst consensus
4 analysts1.50/5
US$1.60Target US$5.03(+796%)US$10.50
Income statement
RevenueUS$1.4M
Gross profitUS$57.2k4% margin
EBITDA-US$63.6M-4498% margin
Net income-US$62.4M-4416.2% margin
Valuation
PER (forward)-4.7x
Beta0.67
Balance sheet & cash
Market capUS$136.6M
Total debtUS$30.2M
Free Cash Flow-US$51.8M
Profitability & ownership
ROA-143.2%
% insiders12.6%
% institutions25.4%
Last declaration on 14 August 2026
Declarations144 total
101,010 sharesCommon StockSEC:0001649989-26-000009:0
Canonical exit: 12 Nov 2026 (T+90)
151,515 sharesCommon StockSEC:0001104659-26-097406:0
Canonical exit: 12 Nov 2026 (T+90)
2,525,252 shares@ US$0.991.53% mcap4.5% of flowCommon StockSEC:0000899140-26-000894:0
Canonical exit: 10 Nov 2026 (T+90)
95,398 shares@ US$1.04820.062% mcap58.7% of flowCommon StockSEC:0001649989-26-000008:0
Canonical exit: 27 Oct 2026 (T+90)
4,285,714 shares@ US$1.4011.0% of flowCommon StockSEC:0000947871-25-000571:0
3,458,571 shares@ US$2.5117.5% of flowCommon StockSEC:0000947871-25-000306:0
5,000 shares@ US$5.6892100.0% of flowCommon StockSEC:0001415889-24-024093:0
Canonical exit: 25 Dec 2024 (T+90)
714,286 sharesCommon StockSEC:0001415889-24-011064:0
Canonical exit: 14 Jul 2024 (T+90)
1,881.711 shares@ US$11.8228.6% of flowCommon StockSEC:0001415889-24-009394:0
Canonical exit: 26 Jun 2024 (T+90)
2,305,714 sharesCommon StockSEC:0000947871-24-000291:0
62,484 shares@ US$0.426.5% of flowCommon StockSEC:0001415889-24-007516:0
Canonical exit: 5 Jun 2024 (T+90)
520,000 shares@ US$1.13591.0% of flowCommon StockSEC:0001209191-23-025294:0
267,000 shares@ US$1.1173.5% of flowCommon StockSEC:0001209191-23-004732:0
33,738 shares@ US$1.255.9% of flowCommon StockSEC:0001209191-23-004118:1
103,255 shares@ US$1.2217.6% of flowCommon StockSEC:0001209191-23-004118:2
27,162 shares@ US$1.318.8% of flowCommon StockSEC:0001209191-23-004118:0
14,230,418 shares@ US$0.878424.4% of flowCommon StockSEC:0000947871-22-001263:0
3,600 shares@ US$1.274.8% of flowCommon StockSEC:0001209191-22-053354:1
Canonical exit: 5 Jan 2023 (T+90)
30,000 shares@ US$1.2926.4% of flowCommon StockSEC:0001209191-22-053357:0
Canonical exit: 5 Jan 2023 (T+90)
29,743 shares@ US$1.2954.4% of flowCommon StockSEC:0001209191-22-053354:0
Canonical exit: 4 Jan 2023 (T+90)
15,662 shares@ US$1.232.9% of flowCommon StockSEC:0001209191-22-052778:1
Canonical exit: 3 Jan 2023 (T+90)
95,541 shares@ US$1.2934.2% of flowCommon StockSEC:0001209191-22-052778:0
Canonical exit: 2 Jan 2023 (T+90)
33,199 shares@ US$1.266.3% of flowCommon StockSEC:0001209191-22-051912:1
Canonical exit: 29 Dec 2022 (T+90)
41,798 shares@ US$1.257.9% of flowCommon StockSEC:0001209191-22-051912:2
Canonical exit: 1 Jan 2023 (T+90)
13,800 shares@ US$1.194.6% of flowCommon StockSEC:0001209191-22-051912:0
Canonical exit: 28 Dec 2022 (T+90)
25 of 144 declarations
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on Nasdaq under the ticker OTLK. Headquartered in Iselin, New Jersey, United States, the company is focused almost entirely on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab intended for retinal diseases, led by wet age-related macular degeneration (wet AMD). For investors, this is a classic late-stage biotech profile: highly concentrated, heavily dependent on regulatory milestones, and therefore very sensitive to FDA decisions, clinical readouts and commercial-launch execution.
The company’s roots date back to 2010, with operations beginning in 2011. It was later reincorporated in Delaware in 2015 and renamed Outlook Therapeutics, reflecting a strategic pivot toward ophthalmology. Over time, the business has been built around a single core asset and a clear strategic thesis: to offer a standardized, ophthalmic-grade, injectable bevacizumab product for retina specialists. This matters because bevacizumab is already widely used in retinal practice, but often in off-label, repackaged form. Outlook’s objective is to provide an approved formulation that can address quality, labeling and regulatory gaps in that market.
Read moreShow less
The company’s key product is ONS-5010, marketed as LYTENAVA™ in certain jurisdictions. Its primary target indication is wet AMD, although the company has also referenced broader retinal indications such as diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). In practical terms, the commercial opportunity is centered on replacing or supplementing off-label bevacizumab use with an on-label, ophthalmic-specific product. That positioning gives Outlook a differentiated niche, but also exposes it to an intensely competitive anti-VEGF landscape dominated by established branded therapies and low-cost off-label alternatives.
Geographically, Outlook Therapeutics now has an important non-U.S. footprint. The company has obtained regulatory authorization for LYTENAVA™ in the European Union and the United Kingdom, and it has indicated that it has begun or is preparing commercial launch activity in select European markets. This international presence is relevant because it offers a potential revenue bridge while the U.S. regulatory process continues. It also provides some real-world commercial validation outside the United States, which is important for a company whose main value driver still lies ahead.
Recent developments have been dominated by the FDA process. In 2025, Outlook announced FDA acceptance and later resubmission of its biologics license application, but it subsequently received a complete response letter toward the end of the year. In early 2026, the company said it had requested a Type A meeting with the FDA to discuss the CRL and potential paths forward. That sequence underscores the binary nature of the investment case: the stock remains fundamentally a regulatory catalyst story, with substantial risk, but also meaningful upside if the company can secure a successful U.S. path for its lead asset.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
